ERBB2 and breast carcinoma: Several Phase III trials are evaluating ICIs and PARPis in various combinations and settings, including ANITA (NCT03598270), ATHENA-COMBO (NCT03522246) [53], DUO-O (NCT03737643), ENGOT ov-44/FIRST (NCT03602859), and ENGOT-ov34/KEYLYNK-001 (NCT03740165), as well as a randomised Phase II trial (NCT02849496) exploring olaparib with or without atezolizumab in BRCA-mutated HER2-negative advanced breast cancer.